Merck announced that its cancer drug Keytruda has been approved to treat a type of head and neck cancer by the U.S. Food and Drug Administration.
According to Merck, Keytruda can now be used as a monotherapy and in combination with a common chemotherapy regimen, to treat previously untreated patients with head and neck squamous cell carcinoma.
The approval is based on a late-stage trial in which Keytruda showed a significant improvement in overall survival in cancer patients.
Keytruda was first approved for advanced melanoma in 2014.
Read the Reuters report.